PROFESSIONAL EDITION

The largest community of pharma leaders

Janux Therapeutics Appoints Andy Meyer Chief Business Officer

SAN DIEGO–()–Janux Therapeutics today announced the appointment of Andy Meyer as Chief Business Officer. Mr. Meyer has more than 10 years of experience in biotechnology as an investment banker at Evercore and BofA Securities, Inc., where he advised biotechnology and life sciences companies on capital raising and strategic matters. At these firms, he successfully executed more than $20 billion in mergers and acquisitions and over 40 capital markets transactions, including initial public offerings (IPOs), follow-ons, convertible notes, and private placements.

“Andy has an excellent scope of experience and accomplishments in finance and strategy for biotech companies,” said David Campbell, Ph.D., President and CEO of Janux Therapeutics. “In this role, Andy will oversee business development and capital formation, as Janux is building a pipeline of next generation T cell engagers to improve the treatment of cancer and advancing our first drug candidate into the clinic in the first half of next year.”

“Janux’s recent financing and pharma partnership provides validation of Janux’s novel approach to directing the power of T cells to fight cancer with the potential to minimize the toxicities that have limited the use of other T cell therapies,” said Mr. Meyer. “The team at Janux has already built tremendous momentum, and I look forward to helping the Company maximize its opportunities.”

Mr. Meyer joins Janux from Evercore, where he served as a Managing Director in the firm’s corporate advisory business with a focus on biotechnology. Prior to joining Evercore, Mr. Meyer spent four years at BofA Securities, Inc. (previously Bank of America Merrill Lynch) in their healthcare investment banking practice. Mr. Meyer received a BSBA in finance from Georgetown University and an MBA from the USC Marshall School of Business.

About T Cell Engagers and Janux’s TRACTr Technology

T cell engagers are an emerging class of immunotherapies that bind to a tumor cell and recruit a patient’s T cells to eradicate tumor cells. Although previous therapies utilizing other technologies have displayed substantial anti-tumor efficacy, they have been constrained by dose-limiting toxicities, poor pharmacokinetic profiles, and attenuated efficacy. Janux’s TRACTr technology is designed to overcome these limitations by integrating tumor-specific activation with crossover pharmacokinetics to produce potentially best-in-class T cell engager therapeutics. In preclinical studies, Janux TRACTr drug candidates have demonstrated comparable anti-tumor efficacy relative to standard T cell engagers but have lacked the associated liabilities related to cytokine release, healthy tissue toxicities, or systemic immune activation.

About Janux Therapeutics

Janux Therapeutics is a preclinical-stage biopharmaceutical company developing novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets. The Janux TRACTr development pipeline targets multiple solid tumor indications, including colorectal, gastroesophageal, prostrate, NSCLC, triple negative breast, and ovarian cancers. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response. Combining Janux’s tumor-specific activation with multi-stage anti-tumor signaling has the potential to significantly improve safety, expand the therapeutic dosing window, and maximize patient responses. For more information, visit www.januxrx.com.

Source

Recent Articles